BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10775792)

  • 41. Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants.
    Santosham M; Englund JA; McInnes P; Croll J; Thompson CM; Croll L; Glezen WP; Siber GR
    Pediatr Infect Dis J; 2001 Oct; 20(10):931-40. PubMed ID: 11642626
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity.
    Latz E; Franko J; Golenbock DT; Schreiber JR
    J Immunol; 2004 Feb; 172(4):2431-8. PubMed ID: 14764714
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines.
    Slack MH; Schapira D; Thwaites RJ; Burrage M; Southern J; Andrews N; Borrow R; Goldblatt D; Miller E
    J Infect Dis; 2001 Dec; 184(12):1617-20. PubMed ID: 11740740
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and reactogenicity of Haemophilus influenzae type b-meningococcus group B outer membrane protein conjugate vaccine in children 2-60 months of age.
    Shehab ZM; Azimi P; Asmar BI; Dunphy MG; Ayoub EM; Dajani AS
    Scand J Infect Dis; 1991; 23(6):763-9. PubMed ID: 1815340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity of Haemophilus influenzae type b polysaccharide-outer membrane protein conjugate vaccine in patients who acquired Haemophilus disease despite previous vaccination with type b polysaccharide vaccine.
    Granoff DM; Chacko A; Lottenbach KR; Sheetz KE
    J Pediatr; 1989 Jun; 114(6):925-33. PubMed ID: 2786062
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of transplacentally acquired tetanus antibodies on the antibody responses to Haemophilus influenzae type b-tetanus toxoid conjugate and tetanus toxoid vaccines in Filipino infants.
    Nohynek H; Gustafsson L; Capeding MR; Käyhty H; Olander RM; Pascualk L; Ruutu P
    Pediatr Infect Dis J; 1999 Jan; 18(1):25-30. PubMed ID: 9951976
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevention of Haemophilus influenzae type b disease.
    Santosham M
    Vaccine; 1993; 11 Suppl 1():S52-7. PubMed ID: 8447177
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative immune responses to Haemophilus influenzae type b polysaccharide and a polysaccharide-protein conjugate vaccine.
    Kim KS; Wong VK; Adler R; Steinberg EA
    Pediatrics; 1990 Apr; 85(4 Pt 2):648-50. PubMed ID: 2107516
    [No Abstract]   [Full Text] [Related]  

  • 50. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom.
    Heath PT; Booy R; Azzopardi HJ; Slack MP; Bowen-Morris J; Griffiths H; Ramsay ME; Deeks JJ; Moxon ER
    JAMA; 2000 Nov; 284(18):2334-40. PubMed ID: 11066183
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose.
    Berrington JE; Cant AJ; Matthews JN; O'Keeffe M; Spickett GP; Fenton AC
    Pediatrics; 2006 Apr; 117(4):e717-24. PubMed ID: 16549502
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.
    Klein NP; Abu-Elyazeed R; Cornish M; Leonardi ML; Weiner LB; Silas PE; Grogg SE; Varman M; Frenck RW; Cheuvart B; Baine Y; Miller JM; Leyssen M; Mesaros N; Roy-Ghanta S
    Vaccine; 2017 Jun; 35(28):3564-3574. PubMed ID: 28536030
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhanced antibody responses in infants given different sequences of heterogeneous Haemophilus influenzae type b conjugate vaccines.
    Greenberg DP; Lieberman JM; Marcy SM; Wong VK; Partridge S; Chang SJ; Chiu CY; Ward JI
    J Pediatr; 1995 Feb; 126(2):206-11. PubMed ID: 7844666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity and safety of Haemophilus influenzae type b polysaccharide-Neisseria meningitidis conjugate vaccine in 7.5 micrograms liquid formulation: a comparison of three lots with the 15.0 micrograms lyophilized formulation. Study Group for 7.5 micrograms Liquid PedvaxHIB.
    Mendelman PM; Feeley L; Bird S; Staub T; Matthews H; Del Beccaro MA; Overturf G; Lee A; Ellis R; Staub J; Szymanski S; Donnelly J; Hennessey JP; Kniskern P
    Vaccine; 1997; 15(6-7):775-81. PubMed ID: 9178481
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster.
    Booy R; Heath PT; Slack MP; Begg N; Moxon ER
    Lancet; 1997 Apr; 349(9060):1197-202. PubMed ID: 9130940
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IgG1, IgG2 and IgM responses to two Haemophilus influenzae type b conjugate vaccines in young infants.
    Ambrosino DM; Sood SK; Lee MC; Chen D; Collard HR; Bolon DL; Johnson C; Daum RS
    Pediatr Infect Dis J; 1992 Oct; 11(10):855-9. PubMed ID: 1408486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines.
    Granoff DM; Holmes SJ; Osterholm MT; McHugh JE; Lucas AH; Anderson EL; Belshe RB; Jacobs JL; Medley F; Murphy TV
    J Infect Dis; 1993 Sep; 168(3):663-71. PubMed ID: 8354908
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
    Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
    Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.
    Iro MA; Khatami A; Marshall AS; Pace D; Voysey M; McKenna J; Campbell D; Attard-Montalto S; Finn A; White C; Faust SN; Kent A; Heath PT; MacLeod E; Stanford E; Findlow H; Almond R; Bai X; Borrow R; Snape MD; Pollard AJ
    Lancet Infect Dis; 2015 Feb; 15(2):172-80. PubMed ID: 25577661
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical experience with PedvaxHIB, a conjugate vaccine of Haemophilus influenzae type b polysaccharide--Neisseria meningitidis outer membrane protein.
    Ahonkhai VI; Lukacs LJ; Jonas LC; Calandra GB
    Vaccine; 1991 Jun; 9 Suppl():S38-41; discussion S42-3. PubMed ID: 1891956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.